Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/CAD.0000000000000239 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Retrospective Analysis of R-COMP Therapy in Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Assessing the Impact of Sample Selection Bias.
J Clin Med
January 2025
Research Unit of Hematology and Stem Cell Transplantation, Fondazione Policlinico Universitario Campus Bio-Medico di Roma, 00128 Rome, Italy.
: Retrospective studies are often criticized for their susceptibility to case selection bias compared to prospective studies, which include all patients consecutively and are thus less prone to such limitations. However, the larger sample sizes typical of retrospective studies can sometimes offset this drawback. On behalf of the Fondazione Italiana Linfomi (FIL), a substantial retrospective study involving 946 patients was conducted to examine the use of non-pegylated liposomal anthracycline (Myocet).
View Article and Find Full Text PDFDoxorubicin or Epirubicin Versus Liposomal Doxorubicin Therapy-Differences in Cardiotoxicity.
Cardiovasc Toxicol
January 2025
Chair and Department of Experimental and Clinical Physiology, Laboratory of Centre for Preclinical Research, Medical University of Warsaw, Banacha 1b, 02-097, Warsaw, Poland.
Doxorubicin (DOX) is an important drug used in the treatment of many malignancies. Unfortunately DOX causes various side effects, with cardiotoxicity being the most characteristic. Risk factors for DOX induced cardiotoxicity (DIC) include cumulative dose of DOX, preexisting cardiovascular diseases, dyslipidemia, diabetes, smoking, along with the use of other cardiotoxic agents.
View Article and Find Full Text PDFEfficient PEGylated magnetic nanoniosomes for co-delivery of artemisinin and metformin: a new frontier in chemotherapeutic efficacy and cancer therapy.
Sci Rep
November 2024
Department of Science, Payame Noor University (PNU), P.O. Box 19395-3697, Tehran, Iran.
Article Synopsis
- - The study developed PEGylated magnetic nanoniosomes (PMNios) for delivering artemisinin (ART) and metformin (MET) in cancer therapy, enhancing drug targeting and bioavailability by modifying the surface with polyethylene glycol and including magnetic nanoparticles.
- - Evaluations showed that PMNios achieved a drug loading efficiency of 88%, with an average size of 298 nm and a stable zeta potential of -19 mV, indicating effective encapsulation and stability.
- - In vitro tests against the A549 lung cancer cell line revealed that PMNios effectively targeted cancer cells, showing appropriate toxicity and lower levels of the anti-apoptotic Bcl2 gene compared to the pro-apoptotic Bax, especially under
Maleimide conjugated PEGylated liposomal antibiotic to combat multi-drug resistant Escherichia coli and Klebsiella pneumoniae with enhanced wound healing potential.
Sci Rep
August 2024
Department of Chemistry, School of Energy Technology, Pandit Deendayal Energy University, Gandhinagar, Gujarat, 382426, India.
Antibiotic resistance is a significant threat, leaving us vulnerable to bacterial infections. Novel strategies are needed to combat bacterial resistance beyond discovering new antibiotics. This research focuses on using maleimide conjugated PEGylated liposomes (Mal-PL-Ab) to individually encapsulate a variety of antibiotics (ceftriaxone, cephalexin, doxycycline, piperacillin, ampicillin, and ceftazidime) and enhance their delivery against multi-drug resistant (MDR) bacteria like Escherichia coli (E.
View Article and Find Full Text PDFQbD Enabled Development and Evaluation of Pazopanib Loaded Nanoliposomes for PDAC Treatment.
AAPS PharmSciTech
May 2024
Translational Pharmaceutics Research Laboratory, Department of Pharmacy, Birla Institute of Technology and Science, Hyderabad, Pilani, India.
Pancreatic ductal adenocarcinoma (PDAC) is one of the highly fatal types of cancer with high mortality/incidence. Considering the crucial role of vascular endothelial growth factor (VEGF) in PDAC progression, its inhibition can be a viable strategy for the treatment. Pazopanib, a second-generation VEGF inhibitor, is approved for the treatment of various oncological conditions.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!